News
Video
Author(s):
Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.
Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches
FDA Approval Insights: Ponatinib in Ph+ ALL
Advancements With Combination Therapies in RCC Usher in New Questions
Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC